FDA Intensifies Crackdown on GLP-1 Compounding

(MedPage Today) -- The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday. Following a review, the...
Source
MedPage Today
Opens original article in a new tab



